Alison Betts Senior Principal Scientist Pfizer Alison graduated from St. Andrews University, Scotland, UK with a first class honors degree in Biochemistry. She started working for Pfizer in the UK in 1994 and transferred to the PDM Translational Research Group in Groton, CT in 2007.
Damayanthi Devineni Director Johnson & Johnson Damayanthi is Director of Clinical Pharmacology at Johnson & Johnson, having received his Ph.D at the University of Georgia. Damayanthi’s expertise lies with the drug-drug interactions in the lower central nervous system.
Glen Smits Consultant Plato BioPharma Glenn has over 25 years of experience in the biopharmaceutical and CRO industries, primarily focused on disease modeling, pharmacology, pharmacokinetics/pharmacodynamics, and safety assessment. Within the CRO industry, Glenn has established and led in vitro and in vivo programs and capabilities to partner with Sponsors and assist them in achieving their drug discovery objectives.
Pierre Daublain Senior Research Chemist Merck Pierre received an engineer diploma from CPE Lyon in 1999. He moved to the US that year to pursue a Ph.D. at the University of Illinois in Chicago and conducted kinetic and mechanistic model studies on coenzyme B12- dependent rearrangements.
Kosalaram Goteti Senior Clinical Pharmacokineticist MedImmune Kosalaram is a Senior Clinical Pharmacokineticist at MedImmune. His expertise include using preclinical PK/PD models to predict synergistic effects of coadministered anti-cancer agents. His work also involves the useful design of the optimal clinical dose.
Hannah Jones Associate Research Fellow Pfizer Hannah is an Associate Research Fellow within the PDM department at Pfizer Inc, Cambridge, MA, US. Hannah is responsible for the modeling and simulation of human PK/PD discovery and early development compounds.
Harriet Kamendi Scientist AstraZeneca Harriet is a DABT certified PhD scientist with seven years experience using in vivo and in vitro approaches to characterize mechanisms of drug action with regards to both efficacy and safety.
Holly Kimko Scientific Director Johnson & Johnson Holly works at Johnson & Johnson Pharmaceutical Research & Development in New Jersey as a member of Advanced Pharmacokinetic/ Pharmacodynamic Modeling and Simulation Department since 2002.
Wojciech Krzyanski Assistant Professor University of Buffalo Wojciech obtained his PhD in Applied Mathematics and MA in Pharmacology from the State University of New York at Buffalo. Currently, he is Associate Professor in the Department of Pharmaceutical Sciences University at Buffalo.
Lucy Lee Clinical Pharmacologist Eisai Lucy graduated with BA/MS from Columbia University, PharmD from University of Maryland, and completed partial PK/PD fellowship at Novartis. She is a diplomate of American Board of Clinical Pharmacology.
Linghui Li Clinical PK/PD Scientist Novartis Linghui has more than six years of experience of experience in design, protocol development, regulatory submission, conduct and results interpretation of clinical pharmacology studies at different phases.
Evelyn Lobo Research Scientist Eli Lilly Evelyn is currently a PK/PD Sr. Research Scientist at Lilly. She received a doctorate in pharmaceutical sciences from the University at Buffaloin 2003. She joined Lilly as a senior pharmacokineticist in 2002.
Pooja Jain Global Sales Development Manager Elsevier Pooja has an MSc degree in Experimental Medicine from McGill University and an MBA from Boston College. Her experience stems from working in respiratory, cardiology, and cancer research labs, a start-up pharmaceutical company in Montreal, Mimetogen Pharmaceuticals, as well as a large pharmaceutical company, Eli Lilly, which all together results in over 10 years of experience. Currently she is working as a Global Sales Development Manager for Elsevier in the PharmaBioTech division.
Tristan Maurer Research Fellow Pfizer Tristan has contributed to 40 peerreviewed journal articles covering the development and application of models to predicting brain penetration, drug-drug interactions, pharmacokinetics and pharmacology.
Wei-Jian Pan Principal Scientist Amgen Wei-Jian received his BPharm from Shanghai Medical University in 1986 and his PhD in 1998. Dr. Pan has more than six years of academic and 13 years of pharmaceutical industry experience involving all phases of non clinical and clinical trials.
Patricia Schroeder Principal Scientist AstraZeneca Patricia is responsible for the preclinical PK/PD translational science package for compounds entering early clinical trials. Patricia began her career in industry at Boehringer Ingelheim (Montreal Canada) in 2005 before moving to AstraZeneca in 2007.
Andrew Stein Senior Modeller Novartis Andrew is a Senior Modeler in the Modeling & Simulation group at Novartis in Cambridge, MA. Previously, he completed a postdoc at the Institute for Mathematics and its Applications.
Stacey Tannenbaum Director Astellas Pharmaceuticals Stacey is a Director of Pharmacokinetics, Modeling, and Simulation at Astellas Pharma Global Development. Her areas of interest include the quantitation of drug action, disease progression, and dose-exposure-response.
Patrick Trapa Senior Principal Scientist Pfizer Patrick leads preclinical modeling and simulations at Pfizer. His group is primarily responsible for supporting projects from early discovery through candidate selection. Patrick received his S.B. and ph.D from MIT in Materials Science and Engineering.
Timothy Waterhouse Senior Research Scientist Eli Lilly Timothy is an expert in population PK/PD. His work involves deigning optimal strategies for the effective use of population PK/PD models at Eli Lilly. Tim has presented at many meeting in the past with the aim of devising better PK/PD models for clinical trials.
Christopher Kemper Consultant PharmaNavigators Christopher is a consultant who’s aim is to provide unparalleled consulting services to the pharmaceutical industry in the speedy development of new drug products. He specialises in strategic & tactical approaches, documentation review and consultation in preclinical drug development.
Dhaval Shah Senior Scientist Pfizer